Cargando…
Treatment of actinic keratoses and cancerization field of the face and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety, tolerability and patients' perspectives
BACKGROUND: Actinic keratosis (AK) represents a risk of progression to squamous cell carcinoma. Ingenol mebutate gel is a novel therapeutic option for field-directed treatment. OBJECTIVES: To evaluate the safety, tolerability and patients' perspectives, related to the therapeutic success of man...
Autores principales: | Gameiro, Luiz, Tovo, Luis Fernando Requejo, Sanches Júnior, José Antonio, Aprahamian, Ivan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668952/ https://www.ncbi.nlm.nih.gov/pubmed/31365660 http://dx.doi.org/10.1590/abd1806-4841.20197938 |
Ejemplares similares
-
Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study
por: Emilio, Joanna, et al.
Publicado: (2016) -
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel
por: Iannazzone, Silvia S., et al.
Publicado: (2018) -
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015%
por: Jung, Yu Seok, et al.
Publicado: (2016) -
The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses
por: Ali, Faisal R., et al.
Publicado: (2012) -
Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis
por: Goldenberg, Gary, et al.
Publicado: (2014)